通用流感疫苗的开发-猫眼课题宝

通用流感疫苗的开发

批准号：

8692600

负责人：

Frank R. Jones

金额：

$139.87万

依托单位：

ETUBICS CORPORATION

依托单位国家：

美国

项目类别：

财政年份：

2014

资助国家：

美国

项目状态：

已结题

起止时间：

2014-04-10 至 2019-03-31

来源：

https://reporter.nih.gov/project-details/8692600

关键词：

Adenoviruses Adverse effects Animal Model Animals Antibodies Antibody Formation Antigen-Presenting Cells Antigens Biodistribution Bioreactors Birds Cancer Model Cancer Patient Carcinoembryonic Antigen Cellular Immunity Clinical Clinical Treatment Clinical Trials Codon Nucleotides Colorectal Cancer Communicable Diseases Consensus Sequence Control Animal DNA-Directed DNA Polymerase Data Development Disease Dose ERBB2 gene Epidemic Ferrets Freeze Drying Freezing Frequencies Future Generations Genes H1N1 vaccine Hemagglutination Hemagglutinin Human Immune Immune response Immunity Immunization Immunotherapeutic agent Infection Influenza Influenza A Virus, H1N1 Subtype Influenza A Virus, H5N1 Subtype Influenza Hemagglutinin Life M2 protein Modeling Mus Nucleoproteins Patients Phase Phase I Clinical Trials Populations at Risk Property Proteins Recombinant Vaccines Recombinants Regimen SIV Safety Serotyping System Technology Testing Therapeutic Toxic effect Toxicology Transgenes Vaccinated Vaccination Vaccine Production Vaccines Virulent Virus Virus Shedding base flu good laboratory practice immunogenic immunogenicity in vivo influenza virus vaccine influenzavirus innovation malignant breast neoplasm metastatic colorectal multiple myeloma M Protein nonhuman primate novel novel vaccines pandemic disease pandemic influenza preclinical study prevent protein expression public health relevance response stability testing tumor vaccine candidate vaccine evaluation vaccinology vector viral DNA

项目摘要

项目成果

Frank R. Jones的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): This application focuses on development of efficacious universal influenza vaccine. Specifically, we will capitalize on the innovative attributes of our new Ad5 [E1-, E2b-] recombinant platform and develop a broadly cross-reactive "flu" vaccine. This will be accomplished by incorporating into our recombinant Ad5 [E1-, E2b-] platform fused transgenes that will express conserved and cross-reactive antigens from the HA, BM2, M2 and NP proteins of influenza A and B strains to be utilized as a new vaccine. The vaccine will be tested in mice and ferrets for its efficacy against various influenza A and B viruses, including highly pathogenic avian H5N1 viruses. In the last years we will perform toxicology and biodistribution studies under GLP and finalize the vaccine stability studies in order to prepare an IND application with the FDA.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文